🇺🇸 FDA
Pipeline program

SPYPBO-102, SPYPBO-101, SPY002, SPY002, SPY001-001, SPY001-001

SPY123-201

Phase 2 small_molecule active

Quick answer

SPYPBO-102, SPYPBO-101, SPY002, SPY002, SPY001-001, SPY001-001 for Moderately to Severely Active Ulcerative Colitis is a Phase 2 program (small_molecule) at Spyre Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Spyre Therapeutics
Indication
Moderately to Severely Active Ulcerative Colitis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials